Autologous cultured chondrocytes on porcine collagen membrane

Vericel Reports Second Quarter 2021 Financial Results and Raises Full-Year 2021 Revenue Guidance

Retrieved on: 
Wednesday, August 4, 2021
Earnings before interest, taxes, depreciation and amortization, Fundamental analysis, Private equity, Profit, Finance, Economy

CAMBRIDGE, Mass., Aug. 04, 2021 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today reported financial results and business highlights for the second quarter ended June 30, 2021.

Key Points: 
  • Gross profit for the quarter ended June 30, 2021 was $26.9 million, or 68% of net revenue, compared to $11.4 million, or 57% of net revenue, for the second quarter of 2020.
  • Net loss for the quarter ended June 30, 2021 was $3.8 million, or $0.08 per share, compared to $8.3 million, or $0.18 per share, for the second quarter of 2020.
  • Non-GAAP adjusted EBITDA for the quarter ended June 30, 2021 was $7.8 million, or 20% of net revenue, compared to an adjusted EBITDA loss of $3.5 million in the second quarter of 2020.
  • To participate in the live call by telephone, please call (877) 312-5881 and reference Vericel Corporations second quarter 2021 investor conference call.

Reversal of Aging of Human Cartilage, Restoring Youthfulness; the First of Its Kind Feat by Edogawa Hospital, Japan.

Retrieved on: 
Wednesday, July 7, 2021
Health, Stem cells, Hospitals, Surgery, Research, Science, Biotechnology, Skeletal system, Anatomy, Branches of biology, Connective tissue, Autologous cultured chondrocytes on porcine collagen membrane, Cartilage, Hyaline cartilage, Chondrocyte, Masatoshi Koshiba, Koshiba, Joint, Knee cartilage replacement therapy

A conversation between (Late) Prof. Masatoshi Koshiba, (Nobel Laureate, 2002) and Dr. Masahiro Katoh on whether his aging joints could be rejuvenated, inspired orthopedician Dr Shojiro Katoh to develop a path breaking EELS-TALC technique (Enriched with Essentials and Lapped in Scaffold, Transplant-suitable Autologous Leveraged Chondrocytes), making this accomplishment.

Key Points: 
  • A conversation between (Late) Prof. Masatoshi Koshiba, (Nobel Laureate, 2002) and Dr. Masahiro Katoh on whether his aging joints could be rejuvenated, inspired orthopedician Dr Shojiro Katoh to develop a path breaking EELS-TALC technique (Enriched with Essentials and Lapped in Scaffold, Transplant-suitable Autologous Leveraged Chondrocytes), making this accomplishment.
  • This press release features multimedia.
  • View the full release here: https://www.businesswire.com/news/home/20210707005420/en/
    Prof. Masatoshi Koshiba (Nobel Laureate; Sitting Rt.)
  • EELS TALC cultured chondrocytes have all ideal characteristics, worth recommending as the most suitable in ACI and MACI treatments:
    (i) Yielding Hyaline cartilage native to articular joints:

Vericel Reports First Quarter 2021 Financial Results and Raises Full-Year 2021 Revenue Guidance

Retrieved on: 
Wednesday, May 5, 2021
Autologous cultured chondrocytes on porcine collagen membrane, Revenue, Maci, Vericel, Du, Chondrocyte, Companies

Total net product revenue for the quarter included $23.8 million of MACI (autologous cultured chondrocytes on porcine collagen membrane) net revenue and $9.8 million of Epicel (cultured epidermal autografts) net revenue, compared to $20.3 million of MACI net revenue and $6.4 million of Epicel net revenue, respectively, in the first quarter of 2020.

Key Points: 
  • Total net product revenue for the quarter included $23.8 million of MACI (autologous cultured chondrocytes on porcine collagen membrane) net revenue and $9.8 million of Epicel (cultured epidermal autografts) net revenue, compared to $20.3 million of MACI net revenue and $6.4 million of Epicel net revenue, respectively, in the first quarter of 2020.
  • A slide presentation with highlights from today\xe2\x80\x99s conference call will be available on the webcast and in the Investor Relations section of the Vericel website.
  • To participate in the live call by telephone, please call (877) 312-5881 and reference Vericel Corporation\xe2\x80\x99s first quarter 2021 investor conference call.
  • Our actual results may differ materially from those expressed or implied by the forward-looking statements in this press release.

Cell Therapy for Cartilage Regeneration Gets a Boost With Hyaluronic Acid Enriched Chondrocytes in a 3D Tissue Engineering Platform

Retrieved on: 
Monday, March 8, 2021
Health, Stem cells, Hospitals, Surgery, Research, Science, Biotechnology, Skeletal system, Anatomy, Branches of biology, Connective tissue, Autologous chondrocyte implantation, Cartilage, Fibrocartilage, Chondrocyte, Hyaline cartilage, Tissue engineering, Autologous cultured chondrocytes on porcine collagen membrane, ACI

Edogawa Evolutionary Laboratory of Science (EELS) researchers accomplished this feat using a 3D tissue engineering scaffold, without externally added HA or growth factors.

Key Points: 
  • Edogawa Evolutionary Laboratory of Science (EELS) researchers accomplished this feat using a 3D tissue engineering scaffold, without externally added HA or growth factors.
  • They hope this technology will improvise the clinical outcome of Autologous Chondrocyte Implantation (ACI) and Matrix Assisted Chondrocyte Implantation (MACI) treatments.
  • The lab environment makes the chondrocytes, many a time, grow as fibrocartilage, whereas, hyaline cartilage is the ideal type of tissue required, which contributes to weight bearing function of the joint.
  • On the contrary, Dr Katoh`s team used a polymer scaffold that retains chondrocyte secreted HA to enhance their growth as a tissue, yielding higher HA content.

Vericel Announces Expansion of MACI Coverage by UnitedHealthcare to Include Patella and Multiple Cartilage Defects in the Knee

Retrieved on: 
Thursday, January 7, 2021
Autologous cultured chondrocytes on porcine collagen membrane, Clinical medicine, Medicine, Branches of biology, Knee cartilage replacement therapy

We are very pleased that United Healthcare has expanded MACI coverage to include patients with patella and multiple cartilage defects in the knee, which is consistent with the MACI label and current clinical practice, said Nick Colangelo, President and CEO of Vericel.

Key Points: 
  • We are very pleased that United Healthcare has expanded MACI coverage to include patients with patella and multiple cartilage defects in the knee, which is consistent with the MACI label and current clinical practice, said Nick Colangelo, President and CEO of Vericel.
  • Since its launch, MACI has become a preferred treatment option, particularly for patients with cartilage defects on the patella, and this updated policy will increase patient access and support continued MACI growth in the years ahead.
  • Vericel is a leader in advanced therapies for the sports medicine and severe burn care markets.
  • MACI (autologous cultured chondrocytes on porcine collagen membrane) is an autologous cellularized scaffold product indicated for the repair of symptomatic, single or multiple full-thickness cartilage defects of the knee with or without bone involvement in adults.

Vericel Provides Business and Financial Updates

Retrieved on: 
Thursday, April 2, 2020
Autologous cultured chondrocytes on porcine collagen membrane, Maci, Vericel

At this time, all Vericel employees not directly involved in the production and delivery of MACI or Epicel are working from home.

Key Points: 
  • At this time, all Vericel employees not directly involved in the production and delivery of MACI or Epicel are working from home.
  • Vericel representatives will also continue to provide field-based support for surgical cases, as needed, in compliance with applicable government mandated business activity restrictions and facility access rules.
  • While our MACI business has been impacted by the restrictions on elective surgical procedures, the fundamentals of our business remain strong.
  • Given the strength of our financial position and the underlying fundamentals of our business, we believe that the Company is well-positioned to maintain its leadership position in the sports medicine and severe burn care markets.

Motili Introduces MACI - the 'Motili Asset Condition Index'

Retrieved on: 
Monday, November 11, 2019
Building engineering, Autologous cultured chondrocytes on porcine collagen membrane, Maci, General contractor, Heating, ventilation, and air conditioning, Construction, Architecture, Property

MACI utilizes data gathered from Motili's asset tagging projects.

Key Points: 
  • MACI utilizes data gathered from Motili's asset tagging projects.
  • MACI provides accurate results about the condition of HVAC and hot water building systems, allowing property owners and operators to make informed decisions regarding capital replacement project planning.
  • Motili leverages contractors, operations teams, and the industry's most advanced Internet platform, to handle work requests from start to finish.
  • Motili handles all aspects of the job from scheduling to ordering equipment to invoicing, making Motili the single point of contact for all property maintenance and equipment replacement.

Growing Demand for Biotechnologies are Expected to Grow

Retrieved on: 
Monday, June 18, 2018
Biology, Biotechnology, Molecular biology, Autologous cultured chondrocytes on porcine collagen membrane, Tissue engineering, Recombinant DNA, DNA sequencing

This is due to the increasing demand for sophisticated biotech-based diagnostic and therapeutic solutions, such as recombinant technology, red biotechnology, DNA sequencing and many more.

Key Points: 
  • This is due to the increasing demand for sophisticated biotech-based diagnostic and therapeutic solutions, such as recombinant technology, red biotechnology, DNA sequencing and many more.
  • This burdensome process effectively dams the wellspring of progress, as potentially life-changing experiments wait for resource availability.
  • As soon as you can buy off the shelf, you don't want to have to build your own microchip.
  • MACI is the first FDA approved product that applies the process of tissue engineering to grow cells on scaffolds using healthy cartilage tissue.